Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Cholinergic Drugs in Pharmacotherapy of Alzheimers Disease

Author(s): Pelayo Camps and Diego Munoz-Torrero

Volume 2, Issue 1, 2002

Page: [11 - 25] Pages: 15

DOI: 10.2174/1389557023406638

Price: $65

Abstract

The cholinergic hypothesis of Alzheimers disease has spurred the development of numerous structural classes of compounds with different pharmacological profiles aimed at increasing central cholinergic neurotransmission, thus providing a symptomatic treatment for this disease. Indeed, the only drugs currently approved for the treatment of Alzheimers disease are cholinomimetics with the pharmacological profile of acetylcholinesterase inhibitors. Recent evidence of a potential disease modifying role of acetylcholinesterase inhibitors and M1 muscarinic agonists have led to a revival of this approach, which might be considered as more than a symptomatic treatment.

Keywords: Cholinergic Drugs, Alzheimers disease, muscarinic agonists, acetylcholine (ACh), Potassium Channel Blockers, Aminoacridines, N-Benzylpiperidines, xanomeline, muscarine


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy